ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting

    Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis

    Laura Cappelli1, J. Lynn Palmer2 and Clifton Bingham III3, 1Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2CORRONA Research Foundation, Phoenix, AZ, 3Johns Hopkins University, Baltimore, MD

    Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…
  • Abstract Number: 1636 • 2016 ACR/ARHP Annual Meeting

    Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study

    Renaud DESBARBIEUX, 59037, CHRU de Lille, Lille, France

    Background/Purpose:  The advent of biological therapies in rheumatoid arthritis has significantly reduced the activity of rheumatoid arthritis, leading to obtaining a remission in a significant…
  • Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting

    Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis

    Maria Hoehle, Rheumatology, Hamburg, Germany

    Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
  • Abstract Number: 1602 • 2015 ACR/ARHP Annual Meeting

    Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study

    Gorica Ristic1, Vesna Subota2, Petar Ristic3, Dejana Stanisavljevic4, Arsen Ristic5, Branislava Glisic1, Milan Petronijevic1 and Dusan Stefanovic1, 1Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, 2Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, 3Department of Endocrinology, Military Medical Academy, Belgrade, Serbia, 4Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia, 5Department of Cardiology, Clinical Center of Serbia & Belgrade University School of Medicine, Belgrade, Serbia

    Background/Purpose: Insulin resistance (IR) is increased and β-cell function impaired in rheumatoid arthritis (RA). The aim of this study was to evaluate whether treatment with…
  • Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting

    Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database

    Brandon Arnieri1, Khaled Sarsour1, David Oliveri1, Attila Pethö-Schramm2, Avani Shah1 and George Quartey1, 1Genentech, South San Francisco, CA, 2F. Hoffmann-La Roche, Basel, Switzerland

    Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
  • Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting

    Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.

    Jose L. Pablos1, Navarro Sarabia F2, Francisco J. Blanco3, Jose Andres Roman Ivorra4, Alberto Alonso5, Emilio Martin-Mola6 and Miguel Cantalejo-Moreira7, 1Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, 2Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, 3Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 4Rheumatology, H.U. P. La Fe, Valencia, Spain, 5H Cruces, Baracaldo, Spain, 6H La Paz, Madrid, Spain, 7Rheumatology Unit, Hospital de Fuenlabrada, Fuenlabrada, Spain

    Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…
  • Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting

    Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry

    Dimitrios A. Pappas1,2, Ani John3, Carol J. Etzel2,4, Chitra Karki2, YouFu Li5, Joel M. Kremer6, Tmirah Haselkorn3 and Jeffrey D. Greenberg2,7, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc, South San Francisco, CA, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5University of Massachusetts Medical School, Worcester, MA, 6Albany Medical College and The Center for Rheumatology, Albany, NY, 7NYU School of Medicine, New York, NY

    Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…
  • Abstract Number: 2753 • 2015 ACR/ARHP Annual Meeting

    Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study

    Naoki Ishiguro1, Tatsuya Atsumi2, Masayoshi Harigai3, Tsuneyo Mimori4, Norihiro Nishimoto5, Takayuki Sumida6, Tsutomu Takeuchi7, Yoshiya Tanaka8, Nobuhiro Takagi9, Ayako Nakasone10 and Hisashi Yamanaka11, 1Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, 2Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 3Department of Phamacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, 4Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, 5Osaka Rheumatology Clinic, Osaka, Japan, 6Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 7Keio University School of Medicine, Tokyo, Japan, 8The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 9Medical Science, Chugai Pharmaceutical, Tokyo, Japan, 10Chugai Pharmaceutical Co. Ltd, Tokyo, Japan, 11Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: The all-patient postmarketing surveillance (PMS) of tocilizumab (TCZ; PMS7901), which followed 7901 rheumatoid arthritis (RA) patients for 28 weeks (wks), showed that patients with…
  • Abstract Number: 2756 • 2015 ACR/ARHP Annual Meeting

    Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry

    Leslie Harrold1,2, Ani John3, George W. Reed2,4, Chitra Karki2, YouFu Li4, Joel M. Kremer5, Tmirah Haselkorn6 and Jeffrey D. Greenberg2,7, 1Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4University of Massachusetts Medical School, Worcester, MA, 5Albany Medical College, Albany, NY, 6Genentech, Inc, South San Francisco, CA, 7NYU School of Medicine, New York, NY

    Background/Purpose: The objective of this real-world analysis was to examine the impact of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) on patient-reported outcomes (PROs) in…
  • Abstract Number: 2771 • 2015 ACR/ARHP Annual Meeting

    Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry

    Leslie Harrold1,2, Ani John3, George W. Reed1,4, Chitra Karki1, YouFu Li4, Joel Kremer5, Tmirah Haselkorn6 and Jeffrey D. Greenberg1,7, 1Corrona, LLC, Southborough, MA, 2Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, 3Genentech, Inc., South San Francisco, CA, 4University of Massachusetts Medical School, Worcester, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6Genentech, Inc, South San Francisco, CA, 7NYU School of Medicine, New York, NY

    Background/Purpose: Little is known regarding the real-world use and effectiveness of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) as monotherapy. The effectiveness of TCZ monotherapy…
  • Abstract Number: 2782 • 2015 ACR/ARHP Annual Meeting

    Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis

    Hiroshi Uda1, Koji Shigematsu2, Yoshitaka Ishizaki2 and Osamu Saiki1,3, 1Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, 2Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan, 3Rheumatology, Shiraishi Hospital, Imabari, Japan

    Background/Purpose: For active rheumatoid arthritis patients with inadequate response to synthetic disease modifying antirheumatic drugs (DMARDs), biologic agents are indicated. However, the cost of biologics,…
  • Abstract Number: 496 • 2015 ACR/ARHP Annual Meeting

    Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate

    Manfred Herold1, Peter Fasching2, Winfried Graninger3, Raimund Lunzer4, Omid Zamani5 and Burkhard Leeb6, 1Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, 2Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, 3Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 4Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, 5Rheumazentrum Favoriten Vienna, Wien, Austria, 62nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria

    Background/Purpose: Increased serum lipid levels in patients being treated with tocilizumab (TCZ) is known from several clinical trials1,2. It is not known whether additional methotrexate…
  • Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity

    Manfred Herold1, Peter Fasching2, Winfried Graninger3, Raimund Lunzer4, Omid Zamani5 and Burkhard Leeb6, 1Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, 2Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, 3Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 4Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, 5Rheumazentrum Favoriten Vienna, Wien, Austria, 62nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria

    Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
  • Abstract Number: 569 • 2015 ACR/ARHP Annual Meeting

    Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy

    Byeongzu Ghang1, Doo-Ho Lim2, Soo Min Ahn3, Wook Jang Seo4, Seokchan Hong3, Yong-Gil Kim2, Chang-Keun Lee2 and Bin Yoo2, 1Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 4Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea

    Background/Purpose: Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is an effective drug for the treatment of rheumatoid arthritis (RA). During administration of tocilizumab, previous studies have…
  • Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting

    Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis

    Masao Sato1 and Masao Takemura2, 1Rheumatology, Matsunami General Hospital, Gifu, Japan, 2Matsunami Reserch Park, Gifu, Japan

    Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology